Eversana Life Sciences Services Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Eversana Life Sciences Services Llc Pharmaceutical Import Records from India — 30 Products, $95.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eversana Life Sciences Services Llc — Pharmaceutical Importer Profile (2026) | 30 Products, $95.9M Trade | TransData Nexus

Eversana Life Sciences Services Llc

Pharmaceutical Importer · United States · Cardiovascular Focus · $95.9M Total Trade · DGFT Verified

Eversana Life Sciences Services Llc is a pharmaceutical importer based in United States with a total trade value of $95.9M across 30 products in 11 therapeutic categories. Based on 2,536 verified import shipments from Indian Customs (DGFT) records, Eversana Life Sciences Services Llc is the #1 buyer in 3 products including Tramadol, Clonazepam, Loperamide. Eversana Life Sciences Services Llc sources from 3 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 99.6% of imports.

Eversana Life Sciences Services Llc — Import Portfolio & Supplier Network

Eversana Life Sciences Services Llc import network — 30 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eversana Life Sciences Services Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$60.9M	1,886	99.6%
Rubicon Research Private Limited	$204.3K	31	0.3%
Aizant Drug Research Solutions Private Limited	$50.0K

What Formulations Does Eversana Life Sciences Services Llc Import?

Formulation	Value	Ships
Pharmaceutical drugs and medicine-	$1.4M	32
Pharma drugs & medi tacrolimus cap 1 MG	$1.3M	30
Phr drugs&medi bupropion TAB USP 300 MG	$937.6K	22
Pharma drugs & medi olmesartan	$887.0K	26
Pharmaceutical drugs and medicine	$814.8K	33
Pharma drugs & medi letrozole TAB USP 2.	$766.6K	25
Pharma drugs & medi levothyroxine 100mcg	$700.7K	19
Phr drugs&medi naltrexone hcl TAB USP	$700.0K	14
Phr drugs&medi bupropion TAB USP 150 MG	$696.7K	17
Pharmaceutical drugs and medicine-	$696.5K	14
Pharma drugs & medi levothyroxine 75 MCG	$580.2K	15
Pharmaceutical drugs and medicine-	$545.4K	14
Pharma drugs & medi diltiazem hcl er	$542.4K	14
Pharma drugs & medi buspiron hcl TAB	$542.2K	18
Pharma drugs & medi eplerenone 25 MG	$530.0K	13

Eversana Life Sciences Services Llc imports 545 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 30 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metoprolol	Cardiovascular	$16.3M	325	2.0%	3
2	Levothyroxine	Diabetes & Endocrine	$12.1M	448	4.1%	6
3	Tacrolimus	Immunosuppressants	$10.8M	215	1.8%	7
4	Tramadol	Analgesics & Antipyretics	$10.1M	202	2.6%	1
5	Clonazepam	CNS & Psychiatric	$7.8M	193	5.6%	1
6	Mycophenolate	Immunosuppressants	$6.3M	127	0.4%	12
7	Carvedilol	Cardiovascular	$4.4M	171	4.5%	6
8	Iron	Vitamins & Supplements	$3.5M	191	0.7%	17
9	Isosorbide	Cardiovascular	$3.4M	105	7.7%	4
10	Amiodarone	Cardiovascular	$3.3M	66	4.4%	3
11	Anastrozole	Advanced Oncology	$3.3M	77	0.5%	8
12	Letrozole	Advanced Oncology	$2.4M	65	2.9%	4
13	Loperamide	Gastrointestinal	$2.4M	47	3.1%	1
14	Etoposide	Oncology	$1.9M	44	3.2%	4
15	Diltiazem	Cardiovascular	$1.3M	26	1.1%	17
16	Fluorouracil	Oncology	$1.1M	21	1.2%	9
17	Bisoprolol	Cardiovascular	$970.0K	25	1.1%	11
18	Hydroxychloroquine	Antimalarial & Antiparasitic	$950.0K	19	0.1%	16
19	Chloroquine	Antimalarial & Antiparasitic	$750.0K	15	0.4%	7
20	Topotecan	Advanced Oncology	$535.5K	18	1.9%	10
21	Gemcitabine	Oncology	$450.0K	9	1.0%	10
22	Ivermectin	Antimalarial & Antiparasitic	$300.0K	6	3.5%	4
23	Pravastatin	Cardiovascular	$300.0K	6	1.0%	15
24	Nitroglycerin	Cardiovascular	$295.0K	75	3.1%	7
25	Mitomycin	Advanced Oncology	$290.9K	15	3.6%	5
26	Ipratropium	Respiratory	$230.5K	12	0.4%	19
27	Busulfan	Advanced Oncology	$179.8K	6	3.6%	7
28	Carmustine	Advanced Oncology	$150.0K	3	0.7%	6
29	Fulvestrant	Advanced Oncology	$100.0K	2	0.7%	15
30	Sirolimus	Immunosuppressants	$100.0K	2	0.7%	7

Eversana Life Sciences Services Llc imports 30 pharmaceutical products across 11 categories into United States totaling $95.9M. The company is the #1 buyer for 3 products: Tramadol, Clonazepam, Loperamide.

Eversana Life Sciences Services Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eversana Life Sciences Services LLC is a leading independent provider of global services to the life sciences industry, specializing in the commercialization of pharmaceutical and healthcare products. The company offers integrated solutions that span all stages of the product lifecycle, delivering long-term, sustainable value for patients, prescribers, channel partners, and payers. Eversana serves over 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Headquartered in Milwaukee, Wisconsin, Eversana operates across the United States and internationally, providing a comprehensive suite of services designed to address the complex needs of pharmaceutical and biotech companies. Their platform integrates consulting, regulatory, marketing, distribution, patient support, and data analytics, enabling clients to outsource the entire commercialization and supply chain process.

2Distribution Network

Eversana's distribution network includes multiple facilities across the United States, with a significant presence in Memphis, Tennessee. The Memphis location, situated at 4580 S Mendenhall Road, serves as a key hub for their logistics operations. Additionally, the company has expanded its global footprint with offices in over fifteen countries, including a recent addition in Berlin, Germany, to enhance its European operations.

The company's logistics capabilities are advanced, incorporating cold-chain expertise and automation to ensure reliable delivery of temperature-sensitive and specialty medications. This infrastructure supports their comprehensive service offerings, including market access, product launch support, and patient services, catering to a diverse clientele across North America, Europe, and Asia-Pacific regions.

3Industry Role

Eversana Life Sciences Services LLC plays a pivotal role in the United States pharmaceutical supply chain as a comprehensive service provider. While not a traditional wholesaler or distributor, the company offers integrated commercialization, logistics, and consulting solutions for pharmaceutical and biotech companies, supporting every stage of the product lifecycle. Their services encompass market access, product launch support, patient services, and data analytics, enabling clients to outsource the entire commercialization and supply chain process.

By integrating these services, Eversana enhances the efficiency and effectiveness of pharmaceutical commercialization, ensuring that products reach the market successfully and patients receive timely access to necessary therapies. This integrated approach positions Eversana as a critical intermediary in the pharmaceutical supply chain, bridging the gap between manufacturers and end-users.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eversana Life Sciences Services Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eversana Life Sciences Services LLC demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $95.9 million USD from India, encompassing 2,536 shipments across 30 products in 11 therapeutic categories. The top five imported products include Metoprolol ($16.3M), Levothyroxine ($12.1M), Tacrolimus ($10.8M), Tramadol ($10.1M), and Clonazepam ($7.8M), collectively accounting for 59.5% of the total import value.

This concentration indicates a strategic sourcing decision, leveraging India's robust pharmaceutical manufacturing capabilities and cost advantages. The reliance on a limited number of suppliers—primarily INTAS Pharmaceuticals Limited, which accounts for 99.6% of the shipments—suggests a stable and well-established relationship. However, such dependency also exposes Eversana to potential risks associated with supply chain disruptions, regulatory changes, or geopolitical factors affecting trade between the United States and India.

2Supply Chain Resilience

Eversana's supply chain resilience is closely tied to its sourcing strategy from India, particularly its reliance on INTAS Pharmaceuticals Limited, which constitutes the vast majority of its imports. This concentrated supplier base may pose risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting trade between the United States and India.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA ensures that imported drugs meet the same standards of safety, efficacy, and quality as those produced domestically.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for the FDA's regulatory activities. The Drug Approval Process involves several stages, including preclinical testing, clinical trials, and submission of a New Drug Application (NDA) to the FDA. For foreign manufacturers, the FDA requires a Foreign Drug Establishment Registration and a U.S. Agent designation to facilitate communication and compliance.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are stringent. Foreign manufacturers must register their establishments with the FDA and designate a U.S. Agent to handle communications. Additionally, each drug product must be approved by the FDA, which involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generics.

The FDA recognizes Good Manufacturing Practice (GMP) certifications from other regulatory bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO). However, foreign manufacturers must provide evidence of compliance with FDA standards, which may include inspections and documentation. Wholesale distribution authorization is also required, ensuring that distributors comply with federal and state regulations governing the storage, handling, and distribution of pharmaceutical products.

Eversana Life Sciences Services Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eversana Life Sciences Services LLC's product category focus on cardiovascular, immunosuppressants, and diabetes & endocrine therapies aligns with prevalent health concerns in the United States. The significant import values of Metoprolol, Levothyroxine, Tacrolimus, Tramadol, and Clonazepam indicate a strategic emphasis on these therapeutic areas.

Market demand for these products is driven by the high prevalence of cardiovascular diseases, autoimmune disorders, and endocrine-related conditions in the U.S. population. By focusing on these categories, Eversana addresses critical healthcare needs, positioning itself as a key player in providing essential medications to the market.

2Sourcing Profile

Eversana's sourcing strategy emphasizes the importation of finished pharmaceutical formulations from India, leveraging the country's robust manufacturing capabilities and cost advantages. The company's portfolio

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Eversana Life Sciences Services Llc

What products does Eversana Life Sciences Services Llc import from India?

Eversana Life Sciences Services Llc imports 30 pharmaceutical products across 11 categories. Top imports: Metoprolol ($16.3M), Levothyroxine ($12.1M), Tacrolimus ($10.8M), Tramadol ($10.1M), Clonazepam ($7.8M).

Who supplies pharmaceuticals to Eversana Life Sciences Services Llc from India?

Eversana Life Sciences Services Llc sources from 3 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (99.6% of imports, $60.9M).

What is Eversana Life Sciences Services Llc's total pharmaceutical import value?

Eversana Life Sciences Services Llc's total pharmaceutical import value from India is $95.9M, based on 2,536 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eversana Life Sciences Services Llc focus on?

Eversana Life Sciences Services Llc imports across 11 categories. The largest: Cardiovascular (31.6%), Immunosuppressants (17.9%), Diabetes & Endocrine (12.7%).

Get Full Eversana Life Sciences Services Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.